

12/09/99
JCS95 U.S. PTO

Certificate of Mailing

Date of Deposit December 9, 1999

Label Number: EJ770213925US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Sandra Marxen

Printed name of person mailing correspondence

Sandra Marxen
Signature of person mailing correspondence


JCS95 U.S. PTO
09/456693

12/09/99

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)

Attorney Docket Number	50036/021002
Applicant	Dasa Lipovsek
Title	PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER BINDING PROTEINS
PRIORITY INFORMATION:	
This application claims priority from United States provisional patent application 60/111,737, filed December 10, 1998.	
APPLICATION ELEMENTS:	
Cover sheet	1 page
Specification	31 pages
Claims	7 pages
Abstract	1 page
Drawing	12 pages
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Newly signed for this application;	2 pages
Statement Deleting Inventors	
Sequence Statement	2 pages
Sequence Listing on Paper	5 pages
Sequence Listing on Diskette	One Diskette
Small Entity Statement, which is: <input checked="" type="checkbox"/> Newly signed for this application;	1 page
Preliminary Amendment	
IDS	
Form PTO 1449	

12/09/99

Cited References	
Recordation Form Cover Sheet and Assignment	
Assignee's Statement	
English Translation	
Certified Copy of Priority Document	
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$380	\$380.00
Excess Claims Fee: 66 - 20 x \$9	\$414.00
Excess Independent Claims Fee: 4 - 3 x \$39	\$39.00
Multiple Dependent Claims Fee: \$130	\$130.00
Total Fees:	\$963.00
<input checked="" type="checkbox"/> Enclosed is a check for \$963.00 to cover the total fees. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Karen L. Elbing, Ph.D. Reg. No. 35,238 Clark & Elbing LLP 176 Federal Street Boston, MA 02110 Telephone: 617-428-0200 Facsimile: 617-428-7045	
 Signature	<u>9 December 1999</u> Date

Certificate of Mailing

Date of Deposit December 9, 1999

Label Number: EJ770213925US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20234.

Sandra E. Marxen

Printed name of person mailing correspondence


Signature of person mailing correspondence

APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANT : DASA LIPOVSEK
TITLE : PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND
OTHER BINDING PROTEINS

PATENT
ATTORNEY DOCKET NUMBER: 50036/021002

jc525 U.S. PTO
09/456693
12/09/99

Certificate of Mailing	
Date of Deposit <u>December 9, 1999</u>	Label Number: <u>EJ770213925US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20231.	
<u>Sandra E. Marxen</u> Printed name of person mailing correspondence	<u><i>Sandra E. Marxen</i></u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dasa Lipovsek

Art Unit:

Serial No.:

Examiner:

Filed: December 9, 1999

Title: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS AND OTHER
BINDING PROTEINS

Assistant Commissioner of Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§1.821 through 1.825 and consisting of five pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. §1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.


As required by 37 C.F.R. §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 9 December 1999



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045